Why GeneDX Stock Surged Higher This Week
Shares in genetic testing company GeneDx Holdings (NASDAQ: WGS) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy of Pediatrics' (AAP) updated guidance, which recommends exome and genetic testing as a first-line test for children with global developmental delays (GDDs) and intellectual disabilities (IDs).That's good news for GeneDx because it has these tests. Additionally, it could encourage the increased adoption of genetic testing to identify rare diseases for which GeneDx has a large dataset.Digging into the details of the updated guidance, the report states that "Pursuing genetic diagnosis for GDD/ID allows for accurate prognostication, facilitates surveillance for potential disorder-related complications, provides accurate recurrence risk in families interested in having additional children, and allows for prenatal diagnostic testing and preimplantation genetic diagnosis (PGD)."Continue reading
Shares in genetic testing company GeneDx Holdings (NASDAQ: WGS) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy of Pediatrics' (AAP) updated guidance, which recommends exome and genetic testing as a first-line test for children with global developmental delays (GDDs) and intellectual disabilities (IDs).
That's good news for GeneDx because it has these tests. Additionally, it could encourage the increased adoption of genetic testing to identify rare diseases for which GeneDx has a large dataset.
Digging into the details of the updated guidance, the report states that "Pursuing genetic diagnosis for GDD/ID allows for accurate prognostication, facilitates surveillance for potential disorder-related complications, provides accurate recurrence risk in families interested in having additional children, and allows for prenatal diagnostic testing and preimplantation genetic diagnosis (PGD)."
